Scott Kopetz

Colorectal cancer physician scientist, NCI Colon Task Force Chair, Professor, and Deputy Chair at The University of Texas, MD Anderson Cancer Center.

[Scott Kopetz @skopetz]

Delighted to share the full #FDA approval for first-line #CRC encorafenib + cetuximab w/ either FOLFOX or FOLFIRI.

The impact from BREAKWATER: Median OS doubled: 30.3 vs 15.1 months, higher PFS, ORR

Test for BRAF V600E rapidly and treat in first-line!
https://t.co/IMD5uLjAhC

[Scott Kopetz @skopetz]

Delighted to be able to share these results. FOLFIRI+EC is an additional treatment option for mCRC patients with BRAF V600E tumors where FOLFOX isn't the right chemo backbone.

[The ASCO Post @ASCOPost]

🩺 BREAKWATER update: First-line encorafenib/cetuximab + FOLFIRI showed higher response rates than chemo alone (64% vs 40%) in pts with BRAF V600E–mutant mCRC, with similar safety—"supporting a potential new SOC." #colorectalcancer
@skopetz | #ASCOGI26

🔗 https://t.co/pYH2DXq5ZE

[Scott Kopetz @skopetz]

Exciting to launch this initiative with the full ADAPT team. How is CRC evolving with treatment and through metastases? We will find out. Read about ASCEND-CRC https://t.co/YpMk2uG9ut and the larger ADAPT program https://t.co/ECEXbV2DEJ in @CancerCell

[Anirban Maitra @Aiims1742]

An example of the type of innovative adaptive design trials being supported by @ARPA_H ADAPT program.
Framework for cancer evolution profiling and interception in colorectal cancer: ASCEND-CRC program
https://t.co/yhM9KbVpfD
@skopetz @KimmieNgMD @GIcancerDoc @aparna1024

[Scott Kopetz @skopetz]

https://t.co/hpYOHRigut

[Scott Kopetz @skopetz]

Delighted to join Jean-Nicolas Vauthey and Pierre-Alain Clavien to chair the Colorectal Liver Metastasis Consensus Conference. Based on the Danish-Zurich model and led by international experts, this will establish guidelines for the treatment of CRC liver metastases. #crcsm

[Scott Kopetz @skopetz]

Tumor inflammation predicts better response to nivolumab alone in MSI-H CRC, while high mutational burden predicts benefit from nivolumab + ipilimumab. Our Nat Comm paper dives into CM142 and PD1 ± CTLA4 predictors with lead of @michael_overman. https://t.co/1OjgWPPqDC #crcsm

[Scott Kopetz @skopetz]

Need a primer about the exciting field of ctDNA defined minimal residual disease and genotyping? I had the pleasure of recording an overview of different uses of ctDNA testing for @Medscape Oncology. #crcmrd
https://t.co/MgGUM4vJQc

[Scott Kopetz @skopetz]

Shared some insights on #ctDNA’s power to guide clinical decisions in GI cancers—enabling precision treatment, improved surveillance, and earlier intervention for colorectal cancer patients. Excited by the field’s rapid progress towards personalized care!
https://t.co/dSznBGCkSM

[Scott Kopetz @skopetz]

Exciting science and clinical efficacy in this @MDAndersonNews team science study led by @VanMorrisMD In Cancer Cell.
Triple therapy with IO led to durable responses in BRAF V600E MSS colorectal cancer, showing promise. Randomized study ongoing. #crcsm
https://t.co/yg5gyQRqNK

[Scott Kopetz @skopetz]

INTERCEPT MRD study: TAS-102 cleared ctDNA in 5/15 (33%) CRC pts with MRD at 6mo, vs 2/30 (7%) in controls, with median DFS to 9.4mo vs 5.8mo. Durable? @skopetz, @kanwal_Raghav, @ryanhuey, @christineparse1, @Moverman322, @PiaMorelli9, @adasarimd. #crcsm @MDAndersonNews

[Scott Kopetz @skopetz]

Targeting the YAP-SDC1 axis overcomes resistance to KRASi in GI cancers by blocking SDC1-driven macropinocytosis and RTK activation, offering a promising strategy for KRASi resistance. @wantong_yao @HaoqiangY @CellRepMed #crcsm To the clinic! https://t.co/CwYZwvDXci

[Scott Kopetz @skopetz]

Important team finding: Fusions occur in 1.3% of mCRC w/ focused partner-agnostic ctDNA assay, but vast majority are subclonal after EGFRi and likely wouldn't provide meaningful benefit if targeted.

Keep hunting for the very rare clonal fusions for clinical benefit!

[Nicholas Hornstein @GIMedOnc]

💥New paper out!
We reanalyzed raw sequencing data from 18,558 standard-of-care Guardant360 ctDNA assays in advanced #colorectalcancer using a partner-agnostic fusion caller.
🧬 Fusions in 1.3% of patients
🧪 93% were subclonal — enriched after EGFR therapy
🔗 Clonal fusions linked to MSI-H tumors

💡 Subclonal fusions may signal impending acquired resistance to targeted therapies like EGFR inhibitors — offering a window for earlier intervention.
📄https://t.co/vdGFaM7ovZ

Thanks to Andrew Pellatt for being a great co-fellow and letting me participate in this work along some of the defining leaders in CRC like @VanMorrisMD @skopetz @ryanhuey !

@GuardantHealth @TheGutOncLab @OncoAlert

[Scott Kopetz @skopetz]

Delighted to visit National Cancer Center Hospital East In Tokyo and connect with dear colleagues. Wonderful updates from SCRUM and MONSTAR program, led by @TakayukiYoshin5 and kindly hosted by Dr. Bando. Looking forward to more collaborations on MRD! #crcsm

[Scott Kopetz @skopetz]

Updated precemtabart tocentecan (M9140, CEACAM ADC) data in mCRC presented at ASCO '25: 31% response rate and mPFS of 6.9m in 100% irinotecan pretreated patients. ADCs can overcome TOP1 relative resistance. https://t.co/Jc6dvTo7AD #crcsm

[Scott Kopetz @skopetz]

Precemtabart tocentecan, an anti-CEACAM5 ADC, is active in heavily pretreated metastatic colorectal cancer—median PFS is 6.9 months, and 72% disease control at 12 weeks. First CRC cohort reported in @NatureMedicine. #crcsm

[Scott Kopetz @skopetz]

A nice overview from our talented Dr Fangman and @kanwal_raghav. Worth a read for updates on the rapidly moving field.

[Ben Fangman, MD @benfangman]

Thank you for the opportunity to discuss this important topic in the treatment of patients with #CRC and thankful for the wonderful mentorship of @skopetz and @kanwal_raghav

[Scott Kopetz @skopetz]

A well laid out thread on barriers for PS trainees and the “cliff” after ending formal training, among other barriers. Really highlights the key issues.

[Scott Kopetz @skopetz]

We are delighted to have you join GI Med Onc faculty at @MDAndersonNews and be able to continue the great work you have started with @ParseghianC and others!

[Madhu Eluri, MD @MadhuEluri]

🎉 Excited to stay on as Assistant Professor in GI Medical Oncology at @MDAndersonNews after graduation. Immensely grateful to my mentors & the support of my family and friends. Thankful to our patients and looking forward to working together to #EndCancer 🚀 #CRCSM #CCAhope

[Scott Kopetz @skopetz]

RT MDAndersonNews: Our experts will present their latest research at #ASCO23, including studies of acute lymphoblastic leukemia, KRAS G12C…

[Scott Kopetz @skopetz]

RT CrcTrialsChat: If you missed yesterday's #CRCTrialsChat session on Immune Checkpoint Inhibitors & Combinations for #MSS Stage IV #CRC ,…